Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 19/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2284165 | 1.00 | REN (0.48) | RENKCNH2CYP3A4ALDH1A1MAPT | |
| SCHEMBL2282400 | 0.84 | REN (0.45) | RENKCNH2CYP3A4 | |
| SCHEMBL2282403 | 0.84 | REN (0.45) | RENKCNH2CYP3A4 | |
| SCHEMBL2282415 | 0.83 | REN (0.43) | RENKCNH2CYP3A4 | |
| SCHEMBL2282408 | 0.83 | REN (0.43) | RENKCNH2CYP3A4 | |
| SCHEMBL2284094 | 0.78 | REN (0.54) | RENKCNH2CYP3A4 | |
| SCHEMBL2287043 | 0.78 | REN (0.41) | RENKCNH2CYP3A4 | |
| SCHEMBL3343866 | 0.75 | REN (0.61) | RENKCNH2CYP3A4 | |
| SCHEMBL2289790 | 0.73 | REN (0.79) | RENKCNH2CYP3A4 | |
| SCHEMBL661968 | 0.68 | REN (0.60) | RENCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207783-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207783-A1 | RENIN INHIBITORS | REN, ACE, AGT | REN 1/4885KCNH2 1459/4885CYP3A4 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.